About Alivus
Alivus is a company. The company has 2,021 employees as of February 28, 2025. Alivus offers products and services including Active Pharmaceutical Ingredients and CDMO Services.
- Employees 2021 as on 28 Feb, 2025
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alivus Life Sciences Limited
- Jurisdiction Solapur, Maharashtra, India
-
Annual Revenue
$268.14 M (USD)4.8as on Mar 31, 2024
-
Net Profit
$55.01 M (USD)0.84as on Mar 31, 2024
-
EBITDA
$78.77 M (USD)4.97as on Mar 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
2021
as on Feb 28, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alivus
Alivus is a publicly listed company on the NSE with ticker symbol ALIVUS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alivus
Alivus offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and CDMO Services.
High-value APIs are developed and manufactured for non-commoditized applications in chronic areas
End-to-end support is provided for API production and development processes
People of Alivus
Unlock access to complete
Funding Insights of Alivus
Detailed funding history for Alivus
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alivus
Investment portfolio details for Alivus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alivus
Detailed financials for Alivus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alivus Comparisons
Peer comparison for Alivus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alivus
Detailed competitors of Alivus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alivus
Complete news archive for Alivus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alivus
As of Feb 28, 2025, the latest employee count at Alivus is 2,021.
Annual revenue of Alivus is $268.14M as on Mar 31, 2024.
High-value Active Pharmaceutical Ingredients (APIs) are developed and manufactured by Alivus within the pharmaceutical sector. APIs are supplied to worldwide partners, with emphasis placed on chronic therapeutic areas. End-to-end support is extended through process development, analytical development, and production of APIs and intermediates. Contract development and manufacturing services are provided to clients. Research and development activities are conducted to support medicine quality standards.
Alivus offers Active Pharmaceutical Ingredients and CDMO Services.
Yes, Alivus is publicly traded on NSE under the ticker symbol ALIVUS.
The ticker symbol of Alivus is ALIVUS on NSE.